USP-Compliant Analysis and Robustness Evaluation of Pramipexole by i-Series

Significance of the Topic

Pramipexole is a key pharmaceutical for Parkinson’s disease management. Reliable quantification through USP-compliant HPLC methods is critical for quality control. Upgrading analytical instrumentation can challenge method consistency, making software-driven design space evaluation vital for robust method transfer.

Objectives and Overview of the Study

This work aimed to demonstrate seamless transfer of the USP-specified HPLC method for pramipexole dihydrochloride from the legacy LC-2010 system to the new i-Series LC-2050C equipped with a delay volume compatibility kit. Additionally, it assessed method robustness using LabSolutions MD to generate design spaces for critical performance parameters.

Materials and Methods

Analytical conditions followed USP guidelines: mobile phase A was 67 mmol/L phosphate buffer with 21 mmol/L sodium 1-octanesulfonate (pH 3.0), mobile phase B was A/acetonitrile (50:50), Shim-pack Scepter C18 column (150 × 4.6 mm, 5 μm), flow rate 1.5 mL/min, column temperature 40 °C, injection volume 5 μL, PDA detection at 264 nm. System suitability focused on resolution and symmetry factor. LabSolutions MD performed robustness evaluation under an AQbD framework by varying flow rate (1.4–1.6 mL/min) and oven temperature (39–41 °C) in nine combinations.

Instrumentation Used

• i-Series LC-2050C HPLC system with delay volume compatibility kit
• Legacy LC-2010 HPLC system
• PDA detector
• LabSolutions MD software

Main Results and Discussion

Chromatograms from both systems confirmed delay volume compatibility. Initial system suitability tests yielded resolutions of 10.7 (LC-2050C) and 9.9 (LC-2010) against a ≥6.0 criterion, and symmetry factors of 0.94 and 0.93 (≤2.0 criterion). Design space analysis in LabSolutions MD showed resolution consistently between 11 and 12 and symmetry factor between 0.9 and 1.0 across the variation range, indicating minimal performance variability and robust method behavior independent of operator experience.

Benefits and Practical Applications

• Smooth method transfer between HPLC generations
• Assured compliance with USP requirements
• Automated robustness assessment via design space visualization
• Reduced dependency on chromatographic expertise

Future Trends and Potential Applications

Expansion of AQbD-driven software tools is expected to streamline method development and lifecycle management. Emerging opportunities include real-time system suitability monitoring, predictive machine learning models for chromatographic outcomes, and application across a broader range of pharmaceutical analytes.

Conclusion

The combination of LC-2050C with a delay volume compatibility kit and LabSolutions MD software delivers an efficient, USP-compliant workflow for pramipexole analysis, ensuring robust, transferable, and user-independent chromatographic methods.

References

1 US Pharmacopeia 43-NF38 Pramipexole Dihydrochloride